OTCMKTS:PTNT Palatin Technologies (PTNT) Stock Price, News & Analysis $24.42 0.00 (0.00%) As of 10/1/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartInsider TradesNews and TrendsSEC Filings About Palatin Technologies Stock (OTCMKTS:PTNT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palatin Technologies alerts:Sign Up Key Stats Today's Range$24.42▼$24.4250-Day Range$23.83▼$25.2252-Week Range$23.83▼$28.06Volume72 shsAverage Volume823 shsMarket Capitalization$976.80 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Palatin Technologies, Inc. is a biopharmaceutical company focused on developing medicines that target the melanocortin receptor system, a group of receptors involved in regulating appetite, sexual function, inflammation and immune responses. The company’s research is centered primarily on peptide-based therapeutics designed to selectively activate specific melanocortin receptors. Palatin’s lead commercial product is Vyleesi (bremelanotide), an injectable melanocortin-4 receptor agonist approved by the U.S. Food and Drug Administration for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. The company has also advanced experimental candidates aimed at conditions involving inflammation, immune dysfunction and metabolic disorders, including programs targeting the melanocortin-1 and melanocortin-4 receptors. Founded in 1986 and headquartered in Cranbury, New Jersey, Palatin has historically pursued development and commercialization through collaborations and licensing arrangements with pharmaceutical companies. Its activities have primarily focused on the United States while seeking broader international opportunities through strategic partnerships. The company’s research and development programs and corporate leadership have evolved over time as it advances its melanocortin-based drug candidates.AI Generated. May Contain Errors. Read More Receive PTNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTNT Stock News HeadlinesPalatin Technologies (OTCMKTS:PTNT) Shares Cross Above 200-Day Moving Average - Time to Sell?September 30 at 1:42 AM | americanbankingnews.comPalatin Targets the Next Generation of Rare Obesity Therapies After MC4R Validation (NASDAQ: PTN)September 28, 2026 | markets.businessinsider.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.October 2 at 1:00 AM | Stansberry Research (Ad)Palatin Technologies (OTCMKTS:PTNT) Stock Passes Above 200 Day Moving Average - Time to Sell?September 22, 2026 | americanbankingnews.comWhat the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity OpportunityJuly 22, 2026 | markets.businessinsider.comPalatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That MattersJune 18, 2026 | theglobeandmail.comPalatin Technologies Voluntarily Transfers Stock Listing to NasdaqMay 19, 2026 | theglobeandmail.comPalatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock ExchangeMay 19, 2026 | finanznachrichten.deSee More Headlines PTNT Stock Analysis - Frequently Asked Questions How have PTNT shares performed this year? Palatin Technologies' stock was trading at $5.60 on January 1st, 2026. Since then, PTNT shares have increased by 336.1% and is now trading at $24.42. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (OTCMKTS:PTNT) posted its quarterly earnings data on Wednesday, May, 15th. The biopharmaceutical company reported ($26.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($25.00) by $1.50. Read the conference call transcript. When did Palatin Technologies' stock split? Palatin Technologies shares reverse split before market open on Tuesday, August 12th 2025.The 1-50 reverse split was announced on Tuesday, August 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Palatin Technologies? Shares of PTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2024Today10/02/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:PTNT Previous SymbolPINK:PTNT CIK911216 Webwww.palatin.com Phone(609) 495-2200Fax609-495-2202Employees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($60.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.74 million Net MarginsN/A Pretax Margin-1,590.66% Return on EquityN/A Return on Assets-365.57% Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.38 Sales & Book Value Annual Sales$4.49 million Price / Sales0.22 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-97.68Miscellaneous Outstanding Shares40,000Free Float18,160,000Market Cap$976.80 thousand OptionableNot Optionable Beta1.64 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:PTNT) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palatin Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
